Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) shares traded down 2.7% during trading on Friday . The stock traded as low as $27.28 and last traded at $27.28. 30,346 shares traded hands during trading, a decline of 83% from the average session volume of 176,428 shares. The stock had previously closed at $28.05.
Wall Street Analyst Weigh In
A number of research firms have commented on RAPP. Jefferies Financial Group assumed coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a "buy" rating and a $35.00 target price for the company. Stifel Nicolaus initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a "buy" rating and a $35.00 price target for the company. Finally, TD Cowen assumed coverage on shares of Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a "buy" rating for the company.
Get Our Latest Analysis on RAPP
Rapport Therapeutics Stock Performance
The firm has a 50-day moving average price of $20.92.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($1.02). On average, sell-side analysts forecast that Rapport Therapeutics will post -3.46 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of RAPP. SG Americas Securities LLC bought a new stake in shares of Rapport Therapeutics in the 3rd quarter worth about $101,000. Logos Global Management LP bought a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $4,859,000. Perceptive Advisors LLC acquired a new stake in Rapport Therapeutics during the 2nd quarter worth $17,403,000. The Manufacturers Life Insurance Company bought a new stake in Rapport Therapeutics in the second quarter valued at about $1,757,000. Finally, Millennium Management LLC bought a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at about $2,716,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
